PSP programmes can't prove adherence. Sustainability teams can't quantify device recovery. CFOs are paying EPR fees with nothing to show regulators. These frameworks build the evidence layer all three need.
Most PSP programmes report on enrolled patients, not verified ones. Payers, HTA bodies, and regulators are increasingly demanding field-level evidence that holds up under audit.
Inhalers and injection pens have a documented end-of-life problem. Without a verified return scheme, pharma companies face growing EPR exposure — and no way to demonstrate compliance.
Value-based agreements with payers require verified adherence. A self-reported adherence rate from a patient diary is not the same as a photo-confirmed, geo-validated dose record.
Every pharma company has existing pharmacy and HCP relationships. The verified data collection layer is sitting idle. No app to distribute. No hardware to install. Just a link.
Operational playbooks for pharma PSP and ESG teams — built from real deployments, not whitepaper theory.
Pharma's Scope 3 emissions include every inhaler, pen, and device that ends up in general waste. This framework maps the hidden exposure — and the verified return model that turns a liability into auditable EPR data.
Most return schemes collect less than 5% of eligible devices. This framework maps the exact leak points — patient friction, pharmacy with no collection mandate, no rep integration — and shows the fix.